Prediction: Rocket Lab's Revenue Tops $1.5 Billion in 2027 Without Counting Iridium

Rocket Lab reported record Q2 2026 revenue of $234 million, up 62% year over year, and lifted its backlog 137% to $2.36 billion; management guided Q3 revenue to another record of $250 million-$265 million. Approximately 45% of backlog, or about $1.1 billion, is expected to convert into revenue within 12 months, supporting a forecast for standalone 2027 revenue above $1.5 billion, excluding the pending $8 billion Iridium acquisition. Risks include execution in space-systems deliveries, possible Neutron delays, expanding adjusted EBITDA losses of $17 million-$23 million projected for Q3 versus an $8.8 million Q2 loss, and a valuation near $63 per share that already assumes substantial growth.

Analysis

The key investable distinction is between contracted top-line visibility and economic value creation. RKLB's Space Systems mix can support growth, but it is also working-capital intensive and exposed to milestone acceptance; rapid revenue conversion without improving gross margin or cash conversion would increase the probability that equity financing bridges operating losses and the eventual IRDM transaction. The market is likely to reward bookings near term, but the next 1-3 months should hinge on backlog quality, funded versus unfunded awards, and whether segment margins scale as acquisition-related costs roll off.

The $8B IRDM deal creates a second valuation regime: RKLB is no longer simply a high-growth defense-space platform, but a prospective acquirer of a mature, cash-generative communications asset. That can lower blended earnings volatility after closing, yet financing structure is decisive. Material stock issuance would cap per-share upside; material debt would make rates, integration execution, and IRDM churn materially more relevant. IRDM's most direct catalyst is disclosure of consideration, financing, regulatory timetable, and termination provisions—not standalone operating momentum alone.

Consensus appears to treat Neutron as free upside while assigning limited probability to schedule/cost escalation. A slip may not impair near-term reported revenue, but it can still compress RKLB's multiple because the program underwrites its strategic comparison with SpaceX and future launch-margin assumptions. The more immediate falsifier for the bull case is not a single launch delay: it is two consecutive quarters of bookings below revenue, Space Systems gross-margin deterioration, or EBITDA losses widening despite scale.

Key Decisions for Investors

• Maintain a neutral-to-underweight RKLB stance into the next earnings print; do not chase backlog headlines. Upgrade only if management demonstrates sequential gross-margin expansion and operating cash burn improves while 12-month backlog conversion remains intact. A guidance cut or EBITDA loss materially above the guided range would invalidate the near-term long case.
• Use RKLB as a relative-value short hedge against higher-beta space/defense exposure if the stock rerates on Neutron headlines before a disclosed launch date and test milestones. Target a 3-6 month horizon; cover on verified launch success, accelerating gross margin, or a clearly accretive IRDM financing package.
• Place an alert on IRDM rather than initiate merger arbitrage: transaction consideration, collar terms, financing commitments, and regulatory conditions are missing. If a fixed cash or well-protected stock consideration creates a meaningful spread after announcement, IRDM can become the cleaner event-driven exposure than RKLB.
• Monitor defense satellite primes and component suppliers for second-order evidence of program execution: LHX, NOC, RTX and GD commentary on classified-space budgets, satellite production cadence, and supply constraints can validate or challenge RKLB's Space Systems delivery assumptions over the next 6-12 months.